Clinical Trial Update: A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 3]

View source ↗

Summary

Phase 3 trial of idasanutlin with cytarabine in relapsed/refractory AML was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idasanutlin (Idasanutlin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Leukemia, Myeloid, Acute | Phase 3 | Status: TERMINATED | Results posted: 2021-09-14